ENZYMINHIBITOREN
European patent · EP1963315 · In force
Register entry
- Publication number
- EP1963315
- Application number
- EP06820620
- Kind
- European patent with effect for Switzerland and Liechtenstein
- Status
- In force
- Specification
- Granted
- Filed
- Dec 21, 2006
- Published
- Sep 3, 2008
- Granted
- Oct 8, 2014
- Protection ends at the latest
- Dec 20, 2026
- Next annual fee due
- Dec 31, 2026
- IPC classes
- C07D 471/04 (2006.01)A61K 31/437 (2006.01)A61P 37/08 (2006.01)
- Priority
- GB 0526169 22.12.2005GB 0620884 20.10.2006
- PCT application
- PCT/GB2006/004854 21.12.2006
- PCT publication
- WO2007/072017 28.06.2007
- Filing language
- English
- Source
- Swissreg
History
What the Federal Institute of Intellectual Property published about this title, newest first.
- Jan 1, 2026
Change
Published in Swissreg on 01.01.2026
- Jan 1, 2025
Change
Published in Swissreg on 01.01.2025
- Jan 1, 2024
Change
Published in Swissreg on 01.01.2024
- Jan 1, 2023
Change
Published in Swissreg on 01.01.2023
- Apr 4, 2020
Transferred
- Owner
- Cancer Research Technology Limited, Angel Building, 407 St John Street, London, EC1V 4AD, United Kingdom → The Institute of Cancer Research: Royal Cancer, Hospital, 123 Old Brompton Road, London SW7 3RP, United Kingdom
Published in Swissreg on 04.04.2020
- Feb 7, 2015
Agent entered
- Representative
- MICHELI & CIE SA, 122, Rue de Genève, Case postale 61, 1226 Thônex
Published in Swissreg on 07.02.2015
- Oct 8, 2014
Granted
Published in Swissreg on 08.10.2014
Parties
Holder
Inventor
BAVETSIAS, Vassilios
Sutton, Surrey SM2 5NG, GB
MACDONALD, Edward
Sutton, Surrey SM2 5NG, GB
LINARDOPOULOS, Spyridon
Sutton, Surrey SM2 5NG, GB
The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.